EUBREAST 03 (R) AXSANA: Axillary surgical techniques after neoadjuvant chemotherapy

Below please find

Description

AXSANA PI: Thorsten Kühn Study initiated and sponsored by EUBREAST e.V. Trial design: European prospective multicenter registry on axillary surgical techniques after neoadjuvant chemotherapy. Primary endpoint: Invasive disease-free survival, axillary recurrence rate and quality of life and arm morbidity.

International Steering Board

Prof Dr med Thorsten KühnThe Filderklinik, Filderstadt, Germany and
University of Ulm, Ulm, Germany
Ass Prof Jana de BonifaceKarolinska Instituet and Capio St Goran Hospital
SE – 17176 Stockholm, Sweden
+(46) (0)8 5177 0000
Dr Oreste GentiliniIRCCS San Raffaele Hospital Milan
Via Olgettina, 60
20123 Milan, Italy
+(39) 02 26433999
Univ Prof Dr med Elmar StickelerUniversitätsklinikum Aachen
Pauwelsstraße 30
52071 Aachen, Germany
+(49) 241 90 88400

Organizing Committee

Prof Dr med Thorsten KühnThe Filderklinik, Filderstadt, Germany and
University of Ulm, Ulm, Germany
Prof Dr med Maggie Banys PaluchowskiDepartment of Gynecology and Obstetrics
University Hospital Schleswig-Holstein
Campus Lubeck
Ratzeburger Allee 160
23538 Lubeck, Germany
Dr Steffi HartmannDepartment of Gynecology and Obstetrics
Klinikum Sudstadt Rostock
University of Rostock
Sudring 81
18059 Rostock, Germany
Dr Marina MangoldEsculape – Clinical Research Profession
Marktstraße 17
35075 Gladenbach
Ms Jana Shabbir
Study Coordinator
Klinikum Esslingen GmbH
Department of Obstetrics and Gynecology
Hirschlandstr. 97
73730 Esslingen, Germany
Phone: +49 711 / 3103-3063
E-Mail: shabbir@eubreast.com
Dr Bilge Aktas
International Study Coordinator
EUBREAST e.V
Baumreute 37 D
73730 Esslingen, Germany
E-Mail: aktas@eubreast.com

National Steering Committees

eCRF Documentation

The eCRF documentation is available at https://eubreast-axsana.com

In case of questions do not hesitate to contact us at info@eubreast.com or the Study Coordinator: DR BILGE AKTAS SEZEN. 

Documents

The following documents are available for download:

Current documents in English:

AXSANA Flowchart

Country-specific documents are available here:

Albania

Austria

Azerbaijan

Belgium

Bulgaria

Czech Republic

Finland

Germany:

Greece:

India

Israel

Italy:

 *Please note that from time to time there are minor redactional changes in the protocol (for example, each time the Sponsor adds a new country and therefore a new Head of Steering Committee). When this occurs, the Sponsor only changes the last number of the Protocol. The last substantial amendment made to the Protocol was Version 5.0 (and therefore, the version approved by the ethical committee of the Coordinating Hospital in Italy). Since that approved version of the Protocol, the Sponsor declares to have only made redactional changes to the names of Heads of Steering Committees (5.0.1, 5.0.2, 5.0.3 and so on).

Norway:

Peru:

Poland:

Portugal

Romania:

Slovenia

Spain

Sweden:

Switzerland

Thailand

Turkey

United Kingdom

AXSANA Newsletters

Publications

Conference Proceedings:

Videos (including Initiation Video)

 Video: Prof. Dr. med. Thorsten Kühn – SABCS
Video abstract of the AXSANA publication in Cancers 2021
Before study sites start recruiting patients, they are kindly asked to participate in an initiation presentation either via videoconference or by watching the following video (please inform your National Steering Committee afterwards so that your study site can be considered initiated):
Initiation video in English
Initiation video in German:

The financial support for the AXSANA study has been provided by:

Further, the AXSANA study is supported by:  

In case of questions, do not hesitate to contact us at info@eubreast.com

Become a member to stay updated!
The Benefits of EUBREAST Membership
Enter into a network of renowned international breast surgeons
Access to detailed information on ongoing and previous projects and events
Take part in international cross-border studies
Publish your EUBREAST membership status on your website / social media platforms together with the respective logo.